Efficacy and safety of telitacicept as an add-on therapy for relapsing lupus nephritis: a retrospective cohort study.

Front Immunol · 2026 · PMC13236884 · PMID 42254007

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We also found that although the renal relapse rate at 12 months was lower in the telitacicept group (30%) compared to the control group (45%), this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.